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Abstract
Renal osteodystrophy presents an ongoing challenge for clinicians, despite numerous therapeutic
advances in its management. Hyperphosphatemia is found in approximately 70% of patients
undergoing regular dialysis, and secondary hyperparathyroidism is common. Soft-tissue and
vascular calcifications also often occur in patients with end-stage renal disease. Recently, concern
has developed about potentially adverse consequences associated with certain therapeutic
interventions designed to manage secondary hyperparathyroidism and renal bone disease,
particularly with regard to vascular calcification. Treatment with vitamin D sterols and the use of
large oral doses of calcium as a phosphorus-binding agent, either alone or together with vitamin D
therapy increase the risk of soft-tissue calcification in patients with end-stage renal disease. Vascular
calcification contributes substantially to the development of cardiovascular disease and to high
mortality rates from cardiovascular causes. Therefore, it is appropriate to re-examine the guidelines
for managing renal osteodystrophy in patients undergoing long-term dialysis. Alternative strategies
for managing phosphorus retention are being implemented, and new phosphate-binding agents
are being developed. Vitamin D analogs that may have a greater therapeutic index than calcitriol
are also available for clinical use. The successful development of calcimimetic compounds would
provide another mechanistically distinct therapeutic approach that could be used either alone or
together with vitamin D to more effectively manage secondary hyperparathyroidism.
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R E V I E W
A R T I C L E
INTRODUCTION
In its broadest definition, renal osteodystrophy
encompasses all the disorders of bone and mineral
metabolism that occur in patients with chronic renal
disease (1). Despite numerous therapeutic advances, the
management of renal osteodystrophy presents an ongoing
challenge for clinicians. Hyperphosphatemia is found in
approximately 70% of patients undergoing regular
dialysis, and secondary hyperparathyroidism is common
(2). Soft-tissue and vascular calcifications also occur
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development of overt secondary hyperparathyroidism in
chronic renal failure.
In the past, hypocalcemia was a common biochemical
finding in patients with advanced renal insufficiency and
in those starting dialysis. Two factors largely accounted
for this change (14). First, the calcium content of most
renal diets that are designed to limit phosphorus intake
is less than that required for adequate calcium nutrition.
Second, intestinal calcium absorption is suboptimal in
many patients with renal failure because renal calcitriol
synthesis is impaired (15). Both disturbances can
aggravate secondary hyperparathyroidism if corrective
measures such as dietary calcium supplementation or
treatment with calcitriol are not implemented. This was
often the case during the 1970s and early 1980s when
aluminum-containing compounds were widely used as
phosphate-binding agents, and before calcitriol became
available for clinical use (16).
Because the long-term use of aluminum-containing
medications has numerous adverse consequences, most
patients with end-stage renal disease now use calcium-
containing compounds to manage phosphate retention.
The amounts required, however, exceed the 1500 mg of
elemental calcium recommended by the World Health
Organization to prevent age-related bone loss in the
general population. Indeed, total calcium intake can
approach 3 to 5 g per day, a portion of which is absorbed
from the gastrointestinal tract via passive, vitamin D-
independent mechanisms (17). In the absence of
significant residual renal function, total body calcium
balance can become quite positive, and several reports
have documented that serum calcium concentrations
decrease substantially when calcium-containing,
phosphate-binding medications are discontinued abruptly
in patients with end-stage renal disease (18-20). Such
findings provide evidence that some of the calcium
ingested as phosphate-binding medications enters the
extracellular fluid and contributes to the development
of hypercalcemia in as many as 40% of dialysis patients
who use calcium-containing compounds as the primary
method to manage phosphate retention (21,22). The
concurrent administration of calcitriol or other vitamin
D analogs further increases this risk (23).
In addition, several groups of investigators have noted
that the likelihood of vascular calcification is greater in
dialysis patients who ingest relatively large doses of
calcium-containing, phosphate-binding agents (4,5).
Vascular calcification reduces arterial wall compliance
with adverse hemodynamic consequences. It may also
contribute to the rupture of atherosclerotic plaques with
subsequent arterial thrombosis (24). Because of these
quite often in patients with end-stage renal disease.
Therefore, the available strategies to manage these
problems have been only partially successful.
In recent years, concern has developed about potentially
adverse consequences associated with certain thera-
peutic interventions designed to manage secondary
hyperparathyroidism and renal bone disease, particularly
with regard to vascular calcification. Treatment with
vitamin D sterols can increase serum calcium and
phosphorus levels, and has been shown to increase the
risk of soft-tissue calcification in patients with end-stage
renal disease (3). The use of large oral doses of calcium
as a phosphorus-binding agent, either alone or together
with vitamin D therapy, may further increase this risk
(4,5). Evidence has accumulated to suggest that vascular
calcification contributes substantially to the development
of cardiovascular disease and to high mortality rates from
cardiovascular causes in the end-stage renal disease
population (6,7). These considerations suggest that it is
appropriate to re-examine the guidelines for managing
renal osteodystrophy in patients undergoing long-term
dialysis with the objective of maximizing the benefit and
minimizing the risk.
MAJOR COMPONENTS OF
CLINICAL MANAGEMENT
Hypocalcemia, hyperphosphatemia, and impaired renal
1,25-dihydroxyvitamin D synthesis each contribute to
excess parathyroid hormone (PTH) secretion in patients
with chronic renal failure (8,9). These disturbances are
the target for therapeutic interventions aimed at pre-
venting the development and controlling the progression
of secondary hyperparathyroidism.
Maintenance of serum calcium levels
Hypocalcemia stimulates PTH release directly by
diminishing the level of activation of the calcium-sensing
receptor (CaSR) in the membrane of parathyroid cells
(10). Plasma PTH levels increase within minutes when
blood ionized calcium levels decrease, and variations in
CaSR activity are primarily responsible for the minute-
to-minute control of PTH secretion in vivo. Low ambient
extracellular calcium concentrations also enhance the rate
of pre-pro-PTH gene transcription, ultimately making
more hormone available for secretion; this response,
however, requires many hours (11). Hypocalcemia that
is sustained for days, weeks, or months leads to para-
thyroid gland hyperplasia, a prominent feature of sec-
ondary hyperparathyroidism caused by chronic renal
failure that further contributes to excess PTH secretion
(12). Recent observations suggest that signaling via the
CaSR is an essential mediator of this response (13).
Hypocalcemia must be avoided, therefore, to prevent the
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concerns and because current therapeutic approaches
may contribute inadvertently to excess cardiovascular
morbidity and mortality in patients undergoing long-term
dialysis, alternative methods for managing phosphate
retention and hyperphosphatemia deserve careful
consideration.
In this context, the use of supraphysiological doses of
oral calcium as a method to control phosphate retention
may not be advisable for patients with end-stage renal
disease. One prudent alternative is to limit total daily
calcium intake to a level sufficient to satisfy nutritional
requirements but low enough to prevent total body
calcium balance from becoming markedly positive.
Unfortunately, only limited information is available to
guide the formulation of definitive recommendations.
Modest dietary calcium supplementation is probably
required to maintain net intestinal calcium transport via
passive mechanisms and to offset defects in vitamin D-
dependent intestinal calcium transport in patients with
advanced renal failure. A daily calcium intake in the range
of 1500 to 2000 mg including dietary sources and
amounts prescribed as oral calcium supplements should
satisfy this objective in most patients with end-stage renal
disease without producing overt calcium retention.
For patients with marked hyperphosphatemia where
modest doses of calcium are inadequate to control serum
phosphorus levels, aluminum hydroxide can be used for
periods limited to a few weeks with little risk of
aluminum retention or aluminum toxicity. This approach
may also be suitable for patients with hypercalcemia,
which precludes upward adjustments to prescribed doses
of calcium-containing, phosphate-binding agents. Care
must be taken, however, to avoid the concurrent
administration of compounds such as citrate that can
promote intestinal aluminum absorption.
As a potentially safer alternative, sevelamer, or poly-
allylamine hydrochloride, can be given either alone or
together with modest oral doses of calcium to diminish
intestinal phosphorus absorption and to manage
phosphate retention. Wide-ranging adjustments to the
dose of sevelamer can be made as tolerated to normalize
serum phosphorus levels without inducing episodes of
hypercalcemia. Because sevelamer contains no calcium,
patients with end-stage renal disease who use this agent
exclusively to manage phosphate retention may not ingest
adequate amounts of calcium each day as discussed
previously. It will be necessary, therefore, to provide
moderate supplemental oral doses of calcium to avoid
dietary calcium deprivation in many patients who are
treated with sevelamer, but there is little information that
directly addresses this issue.
Sevelamer also lowers serum total and low density
lymphocyte cholesterol levels (25). This ancillary effect
of treatment may ultimately prove to be beneficial for
patients known to be at risk for developing cardiovascular
disease. Long-term clinical experience with sevelamer
is limited, and ongoing assessments are needed to
confirm its safety and efficacy with continued use.
Compounds that do not contain either calcium or
aluminum offer alternative approaches to managing
phosphate retention, but none are currently available for
clinical use (26,27). Lanthanum carbonate is an effective
phosphate-binding agent in experimental animals, and
clinical trials to assess its safety and efficacy in patients
with end-stage renal disease are ongoing (27).
Preparations such iron citrate, iron chloride, and iron
ammonium citrate have also been evaluated as
phosphate-binding agents (26). The value of these and
other compounds for clinical use will ultimately depend
on their efficacy in controlling serum phosphorus levels,
the ability of patients to consume the large amounts
usually required, the absence of untoward side effects,
and the lack of toxicity with long-term treatment.
Control of serum phosphorus levels
Hyperphosphatemia promotes the development of
parathyroid gland hyperplasia, but the mechanisms
responsible have yet to be clarified. High ambient
phosphorus levels also affect post-transcriptional events
that enhance messenger ribonucleic acid translation and
PTH synthesis (28-31). In the clinical setting, persistent
hyperphosphatemia seems to attenuate the effectiveness
of calcitriol therapy to lower serum PTH levels in patients
with established secondary hyperparathyroidism. Thus,
adequate control of serum phosphorus levels is critical
to successful patient management.
Until recently, most published guidelines for the
management of phosphate retention in patients with end-
stage renal disease recommended that serum phosphorus
levels be maintained at values modestly above the upper
limit of normal. This advice was based, in part, on reports
from the older literature indicating that osteomalacia can
occur in hemodialysis patients who develop persistent
hypophosphatemia during treatment with aluminum
hydroxide (32). Adequate skeletal mineralization does
not occur when serum phosphorus levels are subnormal.
Maintaining serum phosphorus levels above the upper
limit of normal was thought to diminish the risk of
osteomalacia in patients with chronic renal failure.
Despite such theoretical considerations, guidelines about
the optimal range for serum phosphorus concentrations
in patients with end-stage renal disease are being re-
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examined because of several recent observations.
Hyperphosphatemia has been shown to be an
independent risk factor for death in patients undergoing
hemodialysis even after adjusting for established
cardiovascular risks and other comorbid conditions (2).
Death from cardiovascular causes largely accounts for
excess mortality in such patients (7). In a recent study
that documented the presence of coronary artery
calcification in young adult patients undergoing dialysis,
serum phosphorus levels tended to be higher and the
calcium-phosphorus ion product in serum was greater
in patients with evidence of coronary calcification than
in those without this abnormality (4). Such findings
suggest that the adverse consequences of phosphate
retention in patients treated with dialysis include an
increased risk for cardiovascular disease.
Additional studies are needed to determine the
relationship between disturbances in mineral metabolism
and the development of vascular calcification and adverse
cardiovascular outcomes in patients with end-stage renal
disease. It is possible that therapeutic interventions aimed
at managing phosphate retention, such as the use of very
large oral doses of calcium, either alone or in conjunction
with vitamin D, rather than hyperphosphatemia per se,
are primarily responsible. Evidence is accumulating,
however, to suggest that abnormalities in mineral
metabolism and/or the therapeutic interventions designed
to manage them may inadvertently contribute to the
development and progression of vascular disease in
patients undergoing long-term dialysis.
In this regard, alternative dialysis regimens, such as daily
nocturnal hemodialysis and short-duration hemodialysis
that is done 6 days per week, provide strikingly better
control of serum phosphorus levels than conventional
thrice-weekly hemodialysis (33). Such findings strongly
suggest that current dialysis schedules are only
marginally adequate for managing phosphorus retention
in patients who have little or no residual renal function.
In many cases, they are clearly inadequate. Although
necessary and appropriate, efforts to maintain adequate
protein nutrition with its obligatory phosphorus burden
only further compromise the ability of patients to achieve
net neutral total-body phosphorus balance during the
course of the week. Effective control of phosphorus
retention in patients with end-stage renal disease may
thus require a radical departure from traditional
approaches to dialysis management.
Control of excess parathyroid hormone
secretion
Until the late 1980s, the active treatment of secondary
hyperparathyroidism in patients undergoing regular
hemodialysis entailed the use of daily oral doses of
vitamin D sterols. Calcitriol, or 1,25-dihydroxyvitamin
D3, was used predominantly in the United States (US),
whereas alphacalcidol, or 1-alpha-hydroxyvitamin D3,
was available in Europe (23,34,35). Parenteral
preparations of each agent subsequently became
available, and most hemodialysis patients in the US are
now managed using thrice-weekly intravenous doses of
calcitriol or other vitamin D analogs. This approach
assures patient compliance, allows larger cumulative
doses of vitamin D to be given each week, and produces
very high concentrations of calcitriol in serum shortly
after intravenous administration. Although phar-
macokinetic considerations suggest that intermittent
parenteral therapy should be more effective than
treatment with daily oral doses of calcitriol for controlling
excess PTH secretion and reducing plasma PTH levels,
recent clinical studies have failed to demonstrate
substantive differences between these two therapeutic
approaches (36,37). The frequency of episodes of
hypercalcemia and/or hyperphosphatemia also does not
differ between treatment regimens.
Because serum calcium and phosphorus levels often
increase during treatment with calcitriol, other vitamin
D analogs have been developed in an effort to reduce
these two dose-limiting side effects of vitamin D therapy
and to lower the risk of soft-tissue and vascular
calcification (23). Two compounds currently available
for clinical use in the US are 19-nor-1,25-dihy-
droxyvitamin D2, or paricalcitol, and 1-alpha-hydroxy-
vitamin D2, or doxercalciferol (38,39). Both are vitamin
D2 derivatives. A third vitamin D3-derived compound,
22-oxacalcitriol or 22-oxa-1,25-dihydroxyvitamin D3,
is now available for clinical use in Japan.
All three compounds have been shown in clinical trials
to lower serum or plasma PTH levels in patients with
secondary hyperparathyroidism caused by end-stage
renal disease. Indeed, plasma PTH levels decreased by
an average of 25% to 30% during the first few weeks of
treatment with either paricalcitol or doxercalciferol. It
remains uncertain, however, whether the frequency of
episodes of hypercalcemia and/or hyperphosphatemia is
less during treatment with new vitamin D analogs than
with calcitriol. Studies that compare directly the efficacy
and frequency of side effects with each treatment have
yet to be published. Nevertheless, the availability of new
vitamin D analogs may ultimately provide a way of
managing secondary hyperparathyroidism while
diminishing the risk of soft-tissue and vascular
calcification during vitamin D therapy.
Calcimimetic agents are small organic molecules that
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activate the CaSR in the membrane of the parathyroid
cell, thereby inhibiting PTH release. They represent a
novel approach to managing excess PTH secretion
because their mechanism of action differs fundamentally
from that of the vitamin D sterols (40). The efficacy of
calcimimetic agents in reducing plasma PTH levels has
been documented in short-term studies of hemodialysis
patients with secondary hyperparathyroidism, and long-
term clinical trials in larger numbers of patients are
currently underway (41).
In contrast to treatment with vitamin D, serum calcium
concentrations decline modestly and serum phosphorus
levels often decline during calcimimetic therapy in
patients with secondary hyperparathyroidism (42,43).
Thus, several biochemical abnormalities that have been
associated with the development of soft-tissue and
vascular calcification in patients with end-stage renal
disease improve as plasma PTH levels decrease. Because
their mechanisms of action differ, combined therapy with
calcimimetic agents and vitamin D sterols may be a
particularly effective approach to managing excess PTH
secretion in patients with secondary hyperparathyroidism,
particularly those with severe disease.
Activation of the CaSR has been reported to affect several
fundamental cellular processes including proliferation,
differentiation, and apoptosis (44-46). Apart from their
effect to diminish PTH secretion, studies in rats with renal
failure suggest that calcimimetic compounds impede the
development of parathyroid gland hyperplasia (47).
Moreover, signaling via the CaSR seems to be sufficient
to prevent the development of parathyroid gland
hyperplasia in mice with inactivating mutations in the
gene encoding the vitamin D receptor when serum
calcium levels are maintained within the normal range
by dietary maneuvers (13,48). Calcium per se, acting
through its receptor, may therefore have a fundamental
role in modulating parathyroid gland hyperplasia in
chronic renal failure.
CONCLUSIONS
The risks associated with persistent hyperphosphatemia
and with the use of large doses of calcium and vitamin
D to manage renal osteodystrophy in patients with end-
stage renal disease are becoming more widely
recognized. Alternative strategies for managing
phosphorus retention are being implemented, and new
phosphate-binding agents are being developed. Vitamin
D analogs that may have a greater therapeutic index than
calcitriol are also available for clinical use. The
successful development of calcimimetic compounds
would provide another mechanistically distinct
therapeutic approach that could be used either alone or
together with vitamin D to more effectively manage
secondary hyperparathyroidism.
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